• Teva Pharmaceuticals Industries Ltd., of Jerusalem, and the Asthma and Allergy Foundation of America disclosed findings from a recent patient survey on quick-relief metered dose inhaler design.

• Pfizer Inc., of New York, said top-line results from a Phase IIb/IV study of Rapamune (sirolimus) evaluating kidney transplant patients who transitioned from tacrolimus (TAC)-based therapy to Rapamune three months to five months after transplant showed that the primary endpoint was not achieved.

Researchers from the Swedish Lund University have shown that in the autoimmune disorder Sjogren’s disease, many patients had autoantibodies years before they were diagnosed with the disorder.